For our final installment of the Future of Medicine, we highlight the players shaping this industry at a pivotal time.
These key stakeholders, including lawmakers, government agencies and advocacy groups, are contending with the chaotic first few months of the second Trump administration.
They’re navigating through several policy flashpoints. Republicans’ changes to Medicaid will send waves through the health care system. And research funding frozen by the White House has lawmakers in both parties warning about catastrophic effects on America’s capacity to make new biomedical advancements.
We also probably don’t need to tell you that Health and Human Services Secretary Robert F. Kennedy Jr. is upending the federal government’s approach to vaccines, health and safety protocols, pesticides and more.
Federal agencies are evolving as well. The FDA’s Center for Biologics Evaluation and Research and Center for Drug Evaluation and Research are both streamlining approvals and embracing AI in drug development. The Centers for Medicare and Medicaid Services is piloting new models like value-based care and drug price negotiations.
We also unpack the critical influence of organizations in this space. Groups like PhRMA, the American Cancer Society and the National Venture Capital Association are advocating for policies that support innovation, research funding and equitable access.
